News | February 18, 2009

SAVI Device Expands Access to Shorter Breast Cancer Therapy

Feb 18, 2009 - The SAVI applicator significantly expands the number of women who are able to benefit from breast brachytherapy, according to a new, peer-reviewed journal article in Radiotherapy and Oncology.
The article reports on the first 20 patients to receive radiation therapy for early stage breast cancer with the SAVI applicator, at the University of California, San Diego (UCSD). Authored by Dan Scanderbeg, Ph.D., and others, the article appears in the January 2009 issue of the “Green Journal,” as Radiotherapy and Oncology is known.
The UCSD researchers concluded that SAVI expands the patient population eligible for accelerated partial breast irradiation (APBI), a simpler, much shorter course of radiation therapy following lumpectomy surgery for breast cancer.
In the study, 40 percent of the patients had skin separation (distance between the device and the skin surface) of less than 7 mm. This narrow skin spacing made them ineligible for treatment with “balloon” brachytherapy. SAVI has no skin spacing restrictions, as its multiple catheters allow physicians to carefully direct the dose away from the skin.
“SAVI increases the number of women eligible for APBI beyond what is possible with balloon brachytherapy,” said Dr. Scanderbeg. “The dosimetry with SAVI is phenomenal. The ability to customize the dose allows us to easily contour the radiation and minimize exposure to normal tissue.”
In each of the 20 cases, according to the paper, physicians were able to modulate the dose based on patient-specific anatomy to successfully cover the tumor bed, while sparing healthy tissue. SAVI is a single-entry device that delivers radiation as part of breast conservation therapy. By more precisely targeting radiation therapy, the device treats the tissue where cancer is most likely to recur, while minimizing exposure of structures such as the skin, heart, lungs and ribs.
“The availability of SAVI is a positive development for partial breast irradiation, particularly as preliminary indicators point to the equivalence of APBI with traditional whole breast radiation,” said co-author Catheryn Yashar, M.D., chief of breast and gynecological radiation services at the Moores Cancer Center at UCSD.
“The increasing acceptance of APBI, combined with the availability of more APBI devices and a growing preference among women for a shorter course of radiation therapy, is expanding the number of partial breast cases being performed,” Dr. Yashar said. Instead of the six-week course of treatment required by whole breast radiation, treatment with the SAVI applicator lasts just five days.

For more information: www.SAVI.us

Related Content

California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Cleveland Clinic Leads Development of New Guidelines for Radiation in Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 31, 2017
October 31, 2017 — Cleveland Clinic researcher Chirag Shah, M.D., recently led the development of updated guidelines
Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Pelvic Radiation Confirmed as Standard of Care for High-Risk, Early-Stage Endometrial Cancer
News | Brachytherapy Systems, Women's Healthcare | September 28, 2017
In a new phase III trial report, recurrence-free and overall survival rates for women with stage I-II high-risk...
China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | August 30, 2017
iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
Overlay Init